Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Novo Nordisk to cut insulin prices in the U.S.

Published 09/06/2019, 09:19 AM
Updated 09/06/2019, 09:19 AM
© Reuters. FILE PHOTO: Employees stand in the insulin production plant of Danish multinational pharmaceutical company Novo Nordisk in Chartres

© Reuters. FILE PHOTO: Employees stand in the insulin production plant of Danish multinational pharmaceutical company Novo Nordisk in Chartres

COPENHAGEN (Reuters) - Novo Nordisk (CSE:NOVOb) will offer cheaper insulin to U.S. diabetics, the Danish drugmaker said on Friday, in response to criticism over the high price of the medication and after similar moves by rivals Sanofi (PA:SASY) and Eli Lilly (NYSE:LLY).

President Donald Trump has made high prescription drug prices a top issue in the 2016 presidential campaign and said that drug companies were "getting away with murder".

Novo will offer a generic version of its most heavily prescribed insulin drug Novolog, used by about a million U.S. patients, at a 50% discount compared to the current list price, the company said in a statement.

The list price for one vial will be $144.68.

Novo will also introduce a so-called $99 cash card program from Jan 2020, which patients can use to buy three vials or two packs of pens of Novo's analog insulins for a flat cost of $99, which for most diabetics is an adequate supply for one month.

The cost of insulin for treating type 1 diabetes in the United States has nearly doubled over a five-year period, leading some patients to put their own health at risk by rationing the medication.

"While we will continue to do what we can to help address affordability challenges in the short-term, changes within the system are required to make sustainable and meaningful affordability a reality," said Novo in a statement.

In April, France's Sanofi said it would cut the cost of its insulin products to $99 per month for uninsured patients and others who pay cash in the United States.

Eli Lilly started selling a half-price version of its Humalog insulin in May. The list price for Lilly's authorized generic insulin -- sold under the name Insulin Lispro -- is $137.35 per vial.

© Reuters. FILE PHOTO: Employees stand in the insulin production plant of Danish multinational pharmaceutical company Novo Nordisk in Chartres

In April, a U.S. congressional committee called on executives from Novo, Sanofi and Eli Lilly to testify about the rising costs of the lifesaving drug.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.